ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Associate Director, Global Mobility & Immigration at Revolution Medicines - ApplyBlast

Associate Director, Global Mobility & Immigration

Revolution Medicines

1 month ago

3.5 on Glassdoor

Remote

Full Time

Director

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

Revolution Medicines is seeking an experienced leader to direct and evolve its global immigration, mobility, and relocation programs as the company expands internationally. This senior role involves managing U.S. and global immigration, domestic relocation, and international employee moves while serving as a trusted advisor to stakeholders. The position requires developing compliant, scalable solutions and optimizing vendor partnerships to support the organization's growth.

Responsibilities

Lead and oversee U.S. and global immigration programs including work authorization and permanent residence sponsorship
Manage U.S. domestic relocation and international mobility programs including cross-border employee arrangements
Develop and evolve immigration, relocation, and global mobility policies, processes, and governance

Skills

About Revolution Medicines

revmed.com

Headquarters

Redwood City, California, United States

Company Size

201-500 employees

Founded

2014

View Profile

Revolution Medicines (RevMed) is a biopharmaceutical company dedicated to discovering, developing, and delivering novel targeted medicines for patients with cancer. Their mission focuses specifically on "revolutionizing treatment for patients with RAS‑addicted cancers" through precision-targeted therapies. The company emphasizes a science-driven, end-to-end approach from discovery to delivery. RevMed brands its team as "Revolutionaries" committed to transforming outcomes for people with RAS‑driven tumors.